Diadema Partners’s Maze Therapeutics MAZE Stock Holding History

Diadema Partners’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,000	Closed	-$448K	–	210
2026 Q1	$448K	Buy	+15,000	New	+$662K	0.08%	112

Other funds holding MAZE

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Diadema Partners's MAZE Position: Q2 2026 in Review

Diadema Partners sold out of Maze Therapeutics (MAZE) in Q2 2026, closing a stake of 15,000 shares — an estimated $448K sold.

Diadema Partners first reported a position in MAZE in Q1 2026 and held it in 1 quarter. The position peaked at $448K in Q1 2026. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

Diadema Partners reported no remaining Maze Therapeutics position as of Q2 2026 after selling out during the quarter.
Diadema Partners sold 15,000 Maze Therapeutics shares in Q2 2026, an estimated $448K.
Diadema Partners first reported a position in Maze Therapeutics in Q1 2026 and held it in 1 quarter.
Diadema Partners's Maze Therapeutics position peaked at $448K in Q1 2026.
162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.